Innovative therapy for patients with brain metastases: Oral treatments

Barbara Kopf, U. De Giorgi, S. Zago, O. Carminati, G. Rosti, M. Marangolo

Research output: Contribution to journalArticlepeer-review


About 40% of patients with advanced cancer develop metastases in the central nervous system (CNS), mainly from primary tumors of lung, breast and melanoma. In most of cases there are multiple CNS metastases, making surgery or localized radiosurgery not feasible. The current standard of care for these patients is radiation therapy, which can improve neurologic symptoms but does not have any impact on the patient's overall survival. Temozolomide, capecitabine and gefitinib are safe and active in the treatment of CNS metastases from melanoma/recurrent gliomas, breast carcinoma and lung cancer, respectively. New, orally administered drugs hold a great potential for patients with CNS metastases.

Original languageEnglish
Pages (from-to)94-97
Number of pages4
JournalJournal of Chemotherapy
Issue numberSUPPL. 5
Publication statusPublished - Nov 2004


  • Brain metastases
  • Capecitabine
  • Gefitinib
  • Oral treatments
  • Temozolomide

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Microbiology (medical)

Fingerprint Dive into the research topics of 'Innovative therapy for patients with brain metastases: Oral treatments'. Together they form a unique fingerprint.

Cite this